Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - NO.
Intraneural injection of a test dose of local anesthetic in peripheral nerves - does it induce histological changes in nerve tissue?
Capacity for financial decision making in multiple sclerosis.
Redox Events As Modulators of Pathology and Therapy of Neuroinflammatory Diseases.
Evaluation of highly sensitive immunoassay technologies for quantitative measurements of sub-pg/mL levels of cytokines in human serum.
Bacterial meningitis in a patient with multiple sclerosis receiving Tysabri.
A novel function of TBK1 as a target of Cdon in oligodendrocyte differentiation and myelination.
OMIP-033: A comprehensive single step staining protocol for human T- and B-cell subsets.
Parametric Probability Distribution Functions for Axon Diameters of Corpus Callosum.
Population PK-PD Analyses of CD25 Occupancy, CD56(bright) NK Cell Expansion, and Regulatory T Cell Reduction by Daclizumab HYP in Subjects with Multiple Sclerosis.
Methylprednisolone microsphere sustained-release membrane inhibits scar formation at the site of peripheral nerve lesion.
MRI differential diagnosis of suspected multiple sclerosis.
Endogenous hypothermic response to hypoxia reduces brain injury: Implications for modeling hypoxic-ischemic encephalopathy and therapeutic hypothermia in neonatal mice.
Proteolytic regulation of synaptic plasticity in the mouse primary visual cortex: analysis of matrix metalloproteinase 9 deficient mice.
Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis.
Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis.
The value of histopathological diagnosis in the elderly patients with granulomatous dermatoses. Case series.
Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder.
The functional performance status during weekdays and weekends in persons with multiple sclerosis.
Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis.
Association study of two functional single nucleotide polymorphisms of neuropeptide y gene with multiple sclerosis.
The effect of transplanted human Wharton's jelly mesenchymal stem cells treated with IFN-γ on experimental autoimmune encephalomyelitis mice.
Gene expression profiling of the astrocyte transcriptome in multiple sclerosis normal appearing white matter reveals a neuroprotective role.
Complement C3 on microglial clusters in multiple sclerosis occur in chronic but not acute disease: Implication for disease pathogenesis.
Pages
« first
‹ previous
…
761
762
763
764
765
766
767
768
769
…
next ›
last »